Showing results (41-50 of 131) with videos related to
Sort By:
Pageof 14
Hepatology International|May 6, 2016
Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in IndiaAracely Tamayo, Samir R Shah, Shobna Bhatia, et al.Hepatology Communications|January 8, 2020
Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis BAnna S Lok, Fabien Zoulim, Geoffrey Dusheiko, et al.Antiviral Therapy|February 8, 2014
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitorDavid Nelson, Eric M Yoshida, Matthew S Paulson, et al.Digestive Diseases and Sciences|December 24, 2014
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infectionMaria Buti, Naoky Tsai, Joerg Petersen, et al.JCI Insight|January 26, 2018
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitisRohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, et al.Hepatology (Baltimore, Md.)|July 31, 2008
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis CStefan Zeuzem, Eric M Yoshida, Yves Benhamou, et al.Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.Journal of Hepatology|June 11, 2018
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipientsKosh Agarwal, Lluís Castells, Beat Müllhaupt, et al.Journal of Lipid Research|July 14, 2022
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patientsEric J Lawitz, Kelvin W Li, Edna Nyangau, et al.Journal of Hepatology|December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infectionKosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.Pageof 14